Monthly Archives: August 2016

U.S. Radiation Dose Management Market Forecast till 2020

The purpose of this report is to cover the definition, description, and forecast of the U.S. radiation dose management market. It involves deep dive analysis of market segmentation, which comprises of product type, application, and end user. The report also gives the deep insight on, and strategic analysis of, the key players of this market.

The U.S. radiation dose management market is expected to grow at a CAGR of 49.7% from 2015 to 2020.

In this report, the U.S. radiation dose management market has been classified on the basis of product type, application, and end user. Based on product type, the market has been segmented into services and software. Based on application, the market has been segmented into computed tomography, fluoroscopy, radiography & mammography, and nuclear medicine. Based on end user, the market has been segmented into hospitals, diagnostic centers, and research institutes & academic medical centers.

Software is the fastest-growing segment of the market, and is expected to grow at the highest CAGR of 50.3% from 2015 to 2020. Factors such as growing awareness among stakeholders, various industry initiatives taken for radiation dose management through various scientific and media reports, campaigns and safety programs, along with various government initiatives have led to the increased awareness among patients. The growing concern for the risk of over-exposure to radiations is another factor expected to drive the growth of the U.S. radiation dose management market.

The major companies operational in this market include Bayer AG (Germany), GE Healthcare (U.K.), PACSHealth, LLC (U.S.), and Sectra AB (Sweden). Other players includes QAELUM NV (Belgium), Philips Healthcare (Netherlands), FUJIFILM Holdings Corporation (Japan), Novarad Corporation (U.S.) Siemens Healthcare (Germany), Agfa HealthCare (Belgium), Toshiba Medical Systems Corporation (Japan), Bracco Imaging S.p.A (Italy), and McKesson Corporation (U.S.). These companies have adopted various strategies, such as mergers & acquisitions and partnerships, among others, to achieve growth in the U.S. radiation dose management market.

Request for an in-depth table of contents for this report 

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis—industry analysis (industry trends, and PEST analysis), market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging- and high-growth in the country and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to analyze the market, which in turn will help the firms in achieving a greater market share. Firms purchasing the report could use any one or combination of the below mentioned strategies for strengthening their market share.

 

  • Market Penetration: Comprehensive information on top players in the S. radiation dose management market

 

  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the S. radiation dose management market

 

  • S. radiation dose management market Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the U.S. radiation dose management market

 

 Best Selling Reports :

U.S. Army Institute of Surgical Research – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Global Radiation Dose Management Industry 2015 Market Research Report

 

 

Advertisements

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence

Breast CancerSummary

Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. In the past, breast cancer occurred less in women in Asia than women in Western countries. However, recent studies show that breast cancer is being diagnosed more frequently in women living in Asia, especially among younger women.

There have been wide-reaching changes in the breast cancer market over the past four decades, particularly in relation to the usage of targeted therapies, which has increased significantly. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies and targeted therapies. The market is set to be driven by a number of new approvals for drugs and an increased uptake of premium targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.

Scope

The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.
– What are the competitive advantages of the existing novel drugs?
– Are these targeted therapies used to the same magnitude in all the countries assessed?
– What are the factors contributing to the uptake of these drugs in each country?
With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
– Which classes of novel drugs are most prominent within the pipeline?
– Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
– Which Asia-Pacific countries should expect a late launch and a lower uptake of the late-stage pipeline drugs?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
– How do failure rates vary by product stage of development, molecule type, and mechanism of action?
– How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2014-2021 period, the value of the Asia-Pacific markets for breast cancer therapeutics is expected to increase at a compound annual growth rate of 8.5%, from $1.9 billion to over $3.4 billion.
– Which markets make the most significant contribution to the current market size?
– What are the epidemiology trends in these markets?
– Will new market entrants lead to substantial changes in annual therapy costs?
– How will different treatment usage patterns impact growth in the Asia-Pacific markets?
– What are the various trends observed in the market over the forecast period in each of the countries?
Rising breast cancer prevalence and increasing use of premium targeted therapies along with new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
– Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
Various drivers and barriers would influence the market over the forecast period.
– What are the barriers that limit the uptake of premium-priced therapeutics in the accessed countries?
– Which factors are most likely to drive the market in these countries?

Request for an in-depth table of contents for this report 

 Reasons to buy

This report will enable you to –
– Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options
– Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need
– Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty
– Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action
– Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in breast cancer by examining clinical trial data and multi-scenario product forecast projections
– Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain and Japan
– Discover trends in licensing and co-development deals concerning breast cancer products and identify the major strategic consolidations that have shaped the commercial landscape

Best Selling Reports :

United States Breast Imaging Technologies Sales Market Report 2021

Global Cancer Therapeutics and Biotherapeutics Sales Market Report 2021

Transition Therapeutics Inc. (TTH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

 

 

Mayo Clinic – Strategic SWOT Analysis Review

Mayo Clinic

SUMMARY

Mayo Clinic – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

– Business description A detailed description of the companys operations and business divisions.
– Corporate strategy GlobalDatas summarization of the companys business strategy.
– SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
– Company history Progression of key events associated with the company.
– Major products and services A list of major products, services and brands of the company.
– Key competitors A list of key competitors to the company.
– Key employees A list of the key executives of the company.
– Executive biographies A brief summary of the executives employment history.
– Key operational heads A list of personnel heading key departments/functions.
– Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
– Key manufacturing facilities A list of key manufacturing facilities of the company.

Browse full report @ http://www.aarkstore.com/pharmaceuticals-healthcare/176704/mayo-clinic-strategic-swot-analysis-review

Highlights

Mayo Clinic (Mayo) formerly known as Mayo Clinic Jacksonville is a not-for-profit healthcare organization. The organization provides comprehensive medical facilities and programs related to healthcare education, and research and patient care services. It provides treatments for diseases such as cancer, bipolar disorder, brachial plexus injury, tumors, burning mouth syndrome, eating disorders, epilepsy, infectious diseases, lung diseases, melanoma, Alzheimers and Parkinsons disease, temporomandibular joint (TMJ) disorders, womens health, Wilsons disease and Wolff-Parkinson-White (WPW) syndrome, among others. Mayo operates through its various medical departments that include aerospace medicine, allergy, breast cancer, emergency medicine, medical genetics, pathology, radiology, oncology, neurology, nephrology, ophthalmology and others. Mayo Clinic is headquartered in Jacksonville, Florida, the US.

Reasons to Buy

– Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
– Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
– Understand and respond to your competitors business structure and strategies with GlobalDatas detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
– Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

Best Selling Reports :

Mayo Clinic US – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Singapore Telecommunications Limited (Z74) – Financial and Strategic SWOT Analysis Review

Mind C.T.I. Ltd. (MNDO) – Financial and Strategic SWOT Analysis Review

 

%d bloggers like this: